Patients / advocates

GLP-1 drugs can reduce adolescent obesity. Who will pay for years of treatment?

Boehringer Ingelheim is adding a third target to obesity treatment.

Stroke Recovery Needs More Than Scans and Scores

Alzheimer’s Pill Has Finished the Trial. Evidence Has Not.

The Cyclospora Test Was Wrong. Public Trust Cannot Be

The weight came back. Some visceral fat did not. Obesity care may be measuring the wrong outcome

China Just Put a Bispecific ADC Into Esophageal Cancer

A Breast-Cancer Warning Is Hiding in Aggregated Data

Prevention Is Now Alzheimer’s Hardest Trial
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
